Schrodinger(SDGR) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of$33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 New York, May 1, 2024 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to ...